However, in a phase 3 clinical trial (NCT02017717), patients with recurrent GBM received nivolumab (anti-PD1 immunotherapy) showed no notably difference in overall survival (OS) compared with another group who treated with bevacizumab (an anti-VEGF therapy) (13). Here, VEGFA is linked to glioblastoma.